The expression of pluripotency marker oct 3/4 in prostate cancer and benign prostate hyperplasia

Prostate

Volumn 69, Issue 9, 2009, Pages 909-916

  Monsef, Nastaran ^a   Soller, Maria ^a   Isaksson, Margareth ^a   Abrahamsson, Per Anders ^b   Panagopoulos, Ioannis ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Benign prostate hyperplasia; Immunohistochemistry; Oct3 4; POU5F1; Prostate cancer; RT PCR

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AGED; ANTIBODIES; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OCTAMER TRANSCRIPTION FACTOR-3; PLURIPOTENT STEM CELLS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 67049172213     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20934     Document Type: Article

References (30)

1. Vashchenko N, Abrahamsson PA: Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005;47(2):147-155. (Pubitemid 40126970)
2. Schalken JA, van Leenders G: Cellular and molecular biology of the prostate: Stem cell biology. Urology 2003;62(5 Suppl 1):11-20. (Pubitemid 37371885)
3. English HF, Santen RJ, Isaacs JT: Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987;11(3):229-242. (Pubitemid 18004762)
4. Letellier G, Perez MJ, Yacoub M, Levillain P, Cussenot O, Fromont G: Epithelial phenotypes in the developing human prostate. J Histochem Cytochem 2007;55(9):885-890. (Pubitemid 47293834)
5. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M: p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci USA 2005;102(32):11355-11360. (Pubitemid 41153824)
6. Lawson DA, Witte ON: Stem cells in prostate cancer initiation and progression. J Clin Invest 2007;117(8):2044-2050. (Pubitemid 47219544)
7. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS: Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67(7):3153-3161. (Pubitemid 46724852)
8. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL: CD44+CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98(4):756-765. (Pubitemid 351272625)
9. Pesce M, Scholer HR: Oct-4: Control of totipotency and germline determination. Mol Reprod Dev 2000;55(4):452-457. (Pubitemid 30137108)
10. Okuda T, Tagawa K, Qi ML, Hoshio M, Ueda H, Kawano H, Kanazawa I, Muramatsu M, Okazawa H: Oct-3/4 repression accelerates differentiation of neural progenitor cells in vitro and in vivo. Brain Res Mol Brain Res 2004;132(1):18-30. (Pubitemid 39531348)
11. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW: POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63(9): 2244-2250. (Pubitemid 36538633)
12. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L: OCT4 staining in testicular tumors: A sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol 2004; 28(7):935-940. (Pubitemid 38856851)
13. Lee J, Kim HK, Rho JY, Han YM, Kim J: The human OCT-4 isoforms differ in their ability to confer self-renewal. J Biol Chem 2006;281(44):33554-33565. (Pubitemid 46036736)
14. Takeda J, Seino S, Bell GI: Human Oct3 gene family: cDNA sequences, alternative splicing, gene organization, chromosomal location, and expression at low levels in adult tissues. Nucleic Acids Res 1992;20(17):4613-4620.
15. Pain D, Chirn GW, Strassel C, Kemp DM: Multiple retropseudogenes from pluripotent cell-specific gene expression indicates a potential signature for novel gene identification. J Biol Chem 2005;280(8):6265-6268. (Pubitemid 40347250)
16. Liedtke S, Enczmann J, Waclawczyk S, Wernet P, Kogler G: Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 2007;1(4):364-366. (Pubitemid 47506539)
17. Suo G, Han J, Wang X, Zhang J, Zhao Y, Dai J: Oct4 pseudogenes are transcribed in cancers. Biochem Biophys Res Commun 2005;337(4):1047-1051. (Pubitemid 41505231)
18. Panagopoulos I, Moller E, Isaksson M, Mertens F: A PCR/restriction digestion assay for the detection of the transcript variants 1 and 2 of POU5F1. Genes Chromosomes Cancer 2008;47(6):521-529. (Pubitemid 351657187)
19. Zangrossi S, Marabese M, Broggini M, Giordano R, D'Erasmo M, Montelatici E, Intini D, Neri A, Pesce M, Rebulla P, Lazzari L: Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells 2007;25(7):1675-1680. (Pubitemid 47121844)
20. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE: Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005; 26(2):495-502. (Pubitemid 40246573)
21. Gu G, Yuan J, Wills M, Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67(10):4807-4815. (Pubitemid 46910189)
22. Kotoula V, Papamichos SI, Lambropoulos AF: Revisiting OCT4 expression in peripheral blood mononuclear cells. Stem Cells 2008;26(1):290-291.
23. de Jong J, Looijenga LH: Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: History and future. Crit Rev Oncog 2006;12(3-4):171-203. (Pubitemid 46524130)
24. Cauffman G, Liebaers I, Van Steirteghem A, Van de Velde H: POU5F1 isoforms show different expression patterns in human embryonic stem cells and preimplantation embryos. Stem Cells 2006;24(12):2685-2691. (Pubitemid 46053006)
25. Li H, Zhou J, Miki J, Furusato B, Gu Y, Srivastava S, McLeod DG, Vogel JC, Rhim JS. Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells. Exp Cell Res 2008;314(1):92-102. (Pubitemid 350180777)
26. Sotomayor P, Godoy A, Smith G, Huss W: Oct4 expression in benign and prostate cancer neuroendocrine cells. BJU Int 2007;100: (Suppl 3):17-45.
27. Trompetter M, Smedts F, van der Wijk J, Schoots C, de Jong HJ, Hopman A, de la Rosette J: Keratin profiling in the developing human prostate. A different approach to understanding epithelial lineage. Anticancer Res 2008;28(1A):237-243.
28. Isaacs JT: Prostate stem cells and benign prostatic hyperplasia. Prostate 2008;68(9):1025-1034. (Pubitemid 351794166)
29. Roudier MP, True LD, Vessella RL, Higano CS: Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity. J Clin Pathol 2004;57(3):321-323. (Pubitemid 38338851)
30. Sharifi N, Hurt EM, Farrar WL: Androgen receptor expression in prostate cancer stem cells: Is there a conundrum? Cancer Chemother Pharmacol 2008;62(5):921-923.